University of Southern California CRS

Location	5P21 Rand Schrader Clinic, 1300 North Mission Road, Room 349 Los Angeles, CA 90033-1079 United States of America
Phone	323-343-8288
CRS Coordinator	Luis Mendez lmendez@usc.edu 323-409-8283
CRS Leader	Michael Dube mdube@usc.edu 317-630-6119
Studies	A5128: US Genomic Sampling A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study A5359: The LATITUDE Study A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5360: MINMON Study-Monitoring SOF/VEL in Treatment Naïve, Chronic HCV Participants A5332: REPRIEVE Trial A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5395: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19 A5371: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B